Do Allergy Shots Work for Seasonal Allergies? The Evidence for Pollen SCIT

The timing of SCIT initiation relative to pollen season depends on the dosing protocol your allergist uses. For perennial SCIT (the standard US approach), treatment can begin at any time of year, though many allergists prefer starting the build-up phase outside peak pollen season to reduce the risk of seasonal dose reactions. Most patients who begin SCIT in late fall or winter reach therapeutic maintenance doses by the following spring, providing some first-season benefit. For pre-seasonal protocols (more common in Europe), SCIT is concentrated in a 7-12 injection course delivered 3-4 months before pollen season begins, completing treatment before peak exposure. Studies suggest beginning SCIT 3 to 4 months before your peak pollen season maximizes first-season benefit regardless of protocol.

Perennial SCIT is administered year-round throughout the build-up and maintenance phases, regardless of the pollen season. This is the dominant US approach, per Cox et al. AAAAI/ACAAI practice parameters (2011), and typically involves 3 to 5 years of injections. Pre-seasonal SCIT, more commonly used in Europe, delivers a compressed course of 7-12 injections in the months before pollen season, then pauses during and after the season. Clinical evidence supports the efficacy of both approaches. Perennial SCIT requires a longer total commitment but provides protection across overlapping pollen seasons (grass, tree, ragweed) that pre-seasonal courses may not fully address. For patients allergic to multiple seasonal pollen types, perennial dosing is typically preferred in US practice.

Yes, multi-allergen SCIT is the standard US approach for polysensitized patients — and 50 to 80% of seasonal allergy patients react to multiple pollen types. Your allergist designs a custom extract mix targeting your confirmed sensitizations, which may include grass, ragweed, tree pollen, or combinations. One important clinical consideration: mixing extracts in a single vial requires careful compatibility assessment, as some extracts contain proteases that can degrade other allergens. Research by Nelson (2009) reviewed multi-allergen trials and found two-allergen mixes showed consistent efficacy, while mixes of three or more allergens showed more variable results in some studies, likely due to dilution effects on individual allergen concentrations. Your allergist will account for this when designing your treatment vial.

Evidence shows that SCIT for seasonal pollen allergies can reduce asthma symptoms and, in children, may prevent allergic rhinitis from progressing to asthma. The Moller et al. PAT study (2002, n=205 children with grass/birch allergic rhinitis) found significantly lower asthma development during the 3-year SCIT treatment period. Jacobsen et al. 10-year follow-up confirmed an odds ratio of 2.5 favoring SCIT for asthma prevention even 7 years after stopping treatment. For patients who already have seasonal allergic asthma, the Abramson Cochrane review (2010) found SCIT reduces asthma symptom scores (SMD -0.59) and medication use. However, SCIT should not be initiated while asthma is uncontrolled — FEV1 must be above 70% predicted before starting injections.

Completing a 3 to 5 year course of seasonal pollen SCIT typically produces 7 to 12 years of sustained benefit after stopping. The landmark evidence comes from two sources: Durham et al. NEJM 1999 showed that 3-4 years of grass SCIT maintained benefit for at least 3 years post-treatment in a randomized discontinuation design. Eng et al. Allergy 2006 followed pediatric SCIT patients 12 years after stopping and found persistent significant clinical benefit in hayfever symptoms and medication use. Jacobsen et al. Allergy 2007 confirmed the PAT study asthma prevention benefit persisted 7 years after stopping SCIT in children. Monosensitized patients tend to maintain the longest post-treatment benefit; polysensitized patients with ongoing exposure to multiple untreated allergens may see earlier partial relapse.

For grass pollen allergy specifically, SCIT and FDA-approved SLIT tablets (Grastek or Oralair) achieve broadly comparable efficacy, according to the Nelson 2015 Bayesian network meta-analysis which found no significant difference in symptom or medication scores. The clinical decision therefore turns on safety, convenience, and individual patient factors. SLIT tablets have a dramatically better safety profile — zero documented fatalities worldwide versus approximately one SCIT fatality per 2.5 million injections. SLIT tablets are administered at home daily after the first supervised office dose, eliminating weekly clinic visits. SCIT may be preferred for patients allergic to grass plus other pollens requiring a multi-allergen mix, since no single SLIT tablet covers multiple allergen categories simultaneously. Cost comparison depends heavily on insurance coverage for each modality.

Many allergists temporarily reduce or hold the SCIT dose during peak pollen season for patients who are symptomatic, though practice guidelines do not mandate this approach. AAAAI surveillance data (Bernstein 2004, Amin and Liss 2006) found that administering shots during the peak of pollen season was associated with a higher rate of near-fatal and fatal systemic reactions. Common practice is to repeat the last tolerated dose rather than advancing to the next dose level during peak season, or to temporarily reduce by 25-50%. If you cannot attend appointments during your allergy season, discuss gap management with your allergist — most practices have specific dose-adjustment tables for missed shots based on the length of the gap and whether you are in the build-up or maintenance phase.